title: Improved diastolic function in type 2 diabetes after a six month liraglutide treatment.
abstract: OBJECTIVE
  To investigate whether liraglutide improves diastolic function in type 2 diabetes.
  
  
  METHODS
  Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6months. The remaining 11 patients withdrew from liraglutide therapy during the first month, were started on other hypoglycaemic therapies and formed the control group. Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6months.
  
  
  RESULTS
  In the liraglutide group the early diastolic mitral annulus velocity on the lateral (e-lat) and medial (e-med) sides of the mitral annulus increased from 9.2±3.4 to 11.6±4.7cm/s (p<0.001) and from 6.9±1.7 to 8.4±2.6cm/s (p<0.003), respectively. The ratio of early-to-late velocities on the lateral and medial sides of the mitral annulus increased from 0.7±0.3 to 0.9±0.4 (p<0.001) and from 0.5±0.1 to 0.6±0.1 (p<0.02), respectively. The ratio of early diastolic mitral inflow velocity to early diastolic myocardial relaxation velocity decreased from 10.7±4.3 to 8.5±2.5 (p<0.005). No improvements in diastolic function was detected in the control group. Glucose control improved similarly in both groups: HA1bc -1.5% (-17mmol/mol) vs -1.3% (-14mmol/mol), p=0.67.
  
  
  CONCLUSIONS
  In patients with type 2 diabetes, 6months liraglutide treatment was associated with a significant improvement in diastolic function.
authors.affiliation: Unit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Multimedica IRCCS, Milan, Italy.
authors.forename: Fabio
authors.initials: F
authors.lastname: Saponaro
authors.affiliation: Unit of Cardiology, San Giuseppe Hospital, Multimedica IRCCS, Milan, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Sonaglioni
authors.affiliation: Unit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Multimedica IRCCS, Milan, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Rossi
authors.affiliation: Unit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Multimedica IRCCS, Milan, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Montefusco
authors.affiliation: Unit of Cardiology, San Giuseppe Hospital, Multimedica IRCCS, Milan, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Lombardo
authors.affiliation: Unit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Multimedica IRCCS, Milan, Italy.
authors.forename: Guido
authors.initials: G
authors.lastname: Adda
authors.affiliation: Unit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Multimedica IRCCS, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address: maura.arosio@unimi.it.
authors.forename: Maura
authors.initials: M
authors.lastname: Arosio
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D058065:Diabetic Cardiomyopathies / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology*; D003971:Diastole; D004334:Drug Administration Schedule; D015150:Echocardiography, Doppler; D005260:Female; D005500:Follow-Up Studies; D006352:Heart Ventricles / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D000069450:Liraglutide / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016277:Ventricular Function, Left / Q000187:drug effects*; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide
keywords: Diabetic cardiomyopathy; Diabetic heart disease; Diastolic dysfunction; GLP-1 receptor agonist; Liraglutide; Type 2 diabetes